Treatment of chronic proteinuric kidney disease: What next?

Hypertension

Volumn 54, Issue 1, 2009, Pages 29-31

  Benigni, Ariela ^a   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; NIFEDIPINE; RENIN INHIBITOR;

CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; CONSERVATIVE TREATMENT; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG MECHANISM; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; VASOCONSTRICTION;

ANTIHYPERTENSIVE AGENTS; ARTERIES; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY FAILURE, CHRONIC; PEPTIDES, CYCLIC; PROTEINURIA; RECEPTORS, ENDOTHELIN; TREATMENT OUTCOME;

EID: 67649848156     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.133579     Document Type: Note

References (13)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
2. Remuzzi G, Perico N, Benigni A. New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov. 2002;1:986-1001.
3. Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, Remuzzi G. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1993;44:440-444.
4. Barton M. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol. 2008;4:490-501.
5. Benigni A, Corna D, Maffi R, Benedetti G, Zoja C, Remuzzi G. Reno-protective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int. 1998;54: 353-359.
6. Dhaun N, MacIntyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease. Hypertension. 2009;54:113-119.
7. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006;17:2974-2984.
8. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939-946.
9. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.
10. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, Perna A, Remuzzi G. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol. 2008;19:1213-1224.
11. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med. 1995;155:1073-1080.
12. Rump LC. Secondary rise of albuminuria under AT1-receptor blockade: what is the potential role of aldosterone escape? Nephrol Dial Transplant. 2007;22:5-8.
13. Spat A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev. 2004;84:489-539.